Fosun Orinove

Fosun Orinove is a clinical-stage biotechnology company based in Suzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics for oncology. As a key R&D subsidiary of Fosun Pharma, the company focuses on targeting critical pathways in cancer cell survival and proliferation, such as apoptosis and cell cycle regulation. Their lead clinical program, FCN-338, is a selective B-cell lymphoma 2 (BCL-2) inhibitor designed to treat hematologic malignancies including chronic lymphocytic leukemia. The company leverages its expertise in medicinal chemistry to build a robust pipeline of precision medicines. Fosun Orinove aims to deliver transformative treatments to patients through both internal innovation and strategic integration within the broader Fosun healthcare ecosystem.